Clinical trials: Hepatocellular Carcinoma Resectable
Potentially Resectable Hepatocellular Carcinoma
Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion
This study is a single-center, exploratory clinical trial. Eligible patients with liver cancer, after signing the informed consent form, will be screened and enrolled.
- Trial name
- HCC (NCT07738055)
- Testing
- Envafolimab: 400mg, subcutaneous injection Suvemcitug: 2mg/kg, intravenous injection HAIC: Oxaliplatin 85mg/m² + 5-FU 2400-3200mg/m², continuous infusion, every 3 weeks
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma Non-resectable
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Patients with hepatocellular carcinoma often die from intrahepatic disease because current treatment options are limited. Local treatment using 166Ho-radioembolization (166Ho-RE) offers a safe and effective treatment.
- Trial name
- iHEPAR (NCT05114148)
- Testing
- Holmium-166 radioembolization
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Hepatocellular Carcinoma Non-resectable
Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable…
- Trial name
- ExTRACT-HCC (NCT04965454)
- Testing
- Fluorine-18 fluorocholine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Queen's Medical Center
Hepatocellular Carcinoma Non-resectable
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine…
- Trial name
- CCGLC-001 (NCT05713994)
- Testing
- HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Ze-yang Ding, MD
Liver Cancer
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells.
- Trial name
- NCT00040898
- Testing
- Sho-saiko-to
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepato Cellular Carcinoma (HCC)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates…
- Trial name
- ACTION-001 (NCT07487662)
- Testing
- sintilimab, ipilimumab N01, Lenvatinib
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma
The goal of this observational study is to evaluate how well first-line immunotherapy works and investigate its association with immune-related adverse events (irAEs) in Egyptian adults with unresectable hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable, Hepatocellular Carcinoma Metastatic
- Trial name
- NCT07904494
- Testing
- Atezolizumab plus bevacizumab, Durvalumab Plus Tremelimumab
- Where
- 4 sites in Egypt
- Volunteers
- 294 people
- Sponsor
- Assiut University
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable
- Trial name
- NCT07110233
- Testing
- TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma Non-resectable
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) who progressed after prior systemic therapy (targeted ± immunotherapy) are enrolled. Primary endpoint: objective response rate (ORR).
- Trial name
- NCT07192848
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Song Peng
Liver Cancer
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of…
- Trial name
- NCT00093548
- Testing
- alpha fetoprotein adenoviral vector vaccine, alpha fetoprotein plasmid DNA vaccine, sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant
- Sponsor
- Jonsson Comprehensive Cancer Center
HCC - Hepatocellular Carcinoma
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
Tumor recurrence is the leading cause of death and a major bottleneck for long-term survival in patients with hepatocellular carcinoma (HCC).
- Trial name
- Ad-rHCC (NCT07658105)
- Testing
- eparlitozoviril, Control group
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HCC - Hepatocellular Carcinoma
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
This study aims to explore the value of the 'HAIC Apatinib Camrelizumab' triple regimen for perioperative treatment of resectable hepatocellular carcinoma.
- Trial name
- NCT07618546
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC
- Volunteers
- 208 people
- Sponsor
- Henan Cancer Hospital
Liver Metastasis, Liver Tumors
Radioactive Holmium Microspheres for the Treatment of Liver Metastases
The HEPAR study is aimed at determining the safety of radioactive holmium containing microspheres for the treatment of tumors in the liver.
- Trial name
- HEPAR (NCT01031784)
- Testing
- holmium-166 poly lactic acid microspheres, holmium 166 microspheres
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- UMC Utrecht
Resectable Hepatocellular Carcinoma
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is a Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma.
- Trial name
- NCT05578430
- Testing
- Cadonilimab, TACE, Surgery
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
HCV, HCC
the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths in the world.
- Trial name
- ZEPATIER (NCT03110055)
- Testing
- Grazoprevir/Elbasvir, Medical records, Transarterial Chemoembolization
- Volunteers
- 20 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hepatocellular Carcinoma
Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC
This is an observational, multicenter, single arm, prospective study to evaluate safety and tolerability of selective and ultraselective drug eluting beads transcatheter intraarterial chemoembolization (DEB-TACE) with up to 3 ml…
- Trial name
- NCT02670122
- Testing
- DEB-TACE
- Where
- Spain
- Volunteers
- 131 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma
- Trial name
- NCT01425879
- Testing
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
SIRT With Tremelimumab and Durvalumab for Resectable HCC
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular…
- Conditions
- Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
- Trial name
- NCT05701488
- Testing
- Durvalumab, Tremelimumab, SIRT
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Jiping Wang, MD, PhD
Hepatocellular Carcinoma (HCC)
Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Dear Sir/Madam, We would like to invite you to participate in this clinical research, which has been approved by the Medical Ethics Committee of Zhejiang Cancer Hospital.
- Trial name
- HAICI (NCT06741020)
- Testing
- Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary…
- Trial name
- NCT07368023
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital